ARCHIVES

In Brief: VP-16 NDA Approved By FDA Only For Refractory Testicular Cancer; Removed From Group C List

This article is from The Cancer Letter archive.

Vol. 09 No. 46 | December 2, 1983

Download PDF Visit The Full Archive

Related Articles

In Brief: Reagan/Congress Budget Compromise Seems Likely, Would Loosen FY 1982 Spending Limits On NCI

December 11, 1981

In Brief: Taxol Development Is NCI ‘Emergency Priority’, Dodd To Focus ACS Effort On Breast Screening

December 7, 1990

Grossman Leads Neuro-Oncology Society; NYU Recruits Radiation Oncology Director.

January 14, 2000

Cervarix Vaccine Approved To Prevent Cervical Cancer

October 30, 2009

NCI Supercomputer To Be Available To Extramural Scientists

June 8, 1984

HEW Money Bills Mark Up Set May 26

May 20, 1977